Taiwanese biopharmaceutical company Golden Biotechnology Corp disclosed on Wednesday the receipt of approval from the US FDA for its investigational new drug (IND) application for the randomized, double-blinded, placebo-controlled Phase II clinical trial of Antroquinonol (Hocena) for the treatment of mild-to-moderate pneumonia in COVID-19 patients in the US.
The company is now actively promoting the Phase II study for COVID-19 to improve the symptoms of COVID-19 as well as minimize the possible side effects induced during the treatment process. It has applied for the US BARDA's CoronaWatch meeting, the COVID-19 Candidate and Technologies Portal of the National Institutes of Health (NIH) as well as the US emergency authorization (EUA) once Antroquinonol exhibits the significant clinical results in COVID-19 patients.
According to the company, Antroquinonol was found to reduce viral nucleic acid replication and viral protein synthesis in both cell and animal experiments. Prevention of organ and tissue damage was also observed when treating mice with excessive inflammation.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study